The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
The data highlights its RSV vaccine cuts hospitalizations in older adults
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
Duvakitug was well tolerated and safety was consistent with the induction study
Subscribe To Our Newsletter & Stay Updated
